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Abstract 
Purpose: To compare the gene delivery effectiveness of plasmid DNA (pDNA) encapsulated within poly 
(D,L-lactide-co-glycolide) (PLGA) nanoparticles with that adsorbed on PLGA nanoparticles.  
Methods: PLGA nanoparticles were prepared using solvent-evaporation method. To encapsulate pDNA 
within the particles, it was first complexed with cetyltrimethylammonium bromide (CTAB) and then 
added to the oil phase during the synthesis. For the adsorption, PLGA nanoparticles were first modified 
with either CTAB or chitosan and then pDNA was adsorbed on the particle surface by electrostatic 
interaction.  
Results: Nanoparticles encapsulating pDNA exhibited better plasmid loading and protection with 
significantly lower burst release (p < 0.05) compared to that of the nanoparticles with adsorbed plasmid. 
Cell uptake of chitosan-modified nanoparticles by murine neuroblastoma (N2a) cells was significantly (p 
< 0.05) higher than that of chitosan-free nanoparticles. Nanoparticles encapsulating pDNA showed 
higher transfection efficiency (p < 0.05) in N2a cells.  
Conclusion: Encapsulation of pDNA within PLGA nanoparticles presents a potential strategy for gene 
delivery that is superior to pDNA adsorbed on the nanoparticle surface. In addition, encapsulation keeps 
the particle surface free for further modifications such as the addition of targeting ligands. 
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Gene therapy has shown promising results in the 
treatment of a wide range of diseases. Poly (D,L-
lactide-co-glycolide) (PLGA) is a biodegradable 
and biocompatible polymer [1]. Encapsulating 
plasmid DNA (pDNA) in PLGA microspheres 
protects it from enzymatic degradation and 
preserves its bioactivity and its ability to exhibit 
sustained release [2]. 
-----------------------------------------------------------------------------------------------------------------------------------------------------
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Microparticles and PLGA nanoparticles have 
been frequently used to deliver nucleic acids 
after being modified to bear positive charges. 
The positively-charged particles interact with the 
negatively-charged nucleic acids by means of 
electrostatic interactions. Some of the commonly 
used surface modifying materials are chitosan 
[3], cetyltrimethylammonium bromide (CTAB) [4] 
and poly-L-lysine (PLL) [5]. Another approach for 
delivering nucleic acids is by encapsulating them 
within PLGA microparticles or nanoparticles [6]. 
Every approach for encapsulation of PDNA may 
have its own advantages and disadvantages.  
 
However, there are no available studies on the 
identification of comparative differences among 
the various methods of pDNA delivery. 
Furthermore, comparing different methods based 
on what is reported in the literature is arguably 
unreliable because different studies may use 
different materials obtained from different 
suppliers, which would vastly affect nanoparticle 
properties such as PLGA molecular weight and 
hydrophobicity, chitosan molecular weight and 
degree of de-acetylation, and fabrication 
procedure.  
 
The present study was carried out to compare 
pDNA encapsulated in PLGA nanoparticles, with 
pDNA adsorbed onto PLGA nanoparticles, in 
terms of particle size, zeta potential, suspension 
stability, pDNA loading, release profile, cell 







PLGA5004 [lactic to glycolic acid ratio of 50:50, 
intrinsic viscosity (IV) of 0.2 dl/g, and acid 
terminated] was obtained from PURAC 
(Gorinchem, Netherland). Polyvinyl alcohol (PVA; 
MW ~115 kDa, 88 % hydrolysed) was purchased 
from BDH Laboratory Supplies (Poole, England). 
Dichloromethane (DCM), ethyl acetate (EA), 
cetyltrimethylammonium bromide (CTAB), low 
molecular weight chitosan (LCS) of 50 - 190 kDa 
and medium molecular weight chitosan (MCS) of 
190-310 kDa were obtained from Sigma-Aldrich 
(Steinheim, Germany).  Glacial acetic acid (GAA) 
was product of Merck (Hohen-brunn, Germany). 
All other chemicals used in this study were of 
analytical grade unless otherwise stated. Plasmid 
DNA (pDNA)-encoding green fluorescent protein 
(GFP) was generously provided by Dr. Michael 
Bradbury (Mount Sinai School of Medicine, 
Department of Medicine, Manhattan, USA). 
 
 
Nanoparticle synthesis  
 
Five formulations (F1-5) of nanoparticles were 
synthesized by a modified emulsion solvent-
diffusion method [3]. The components of the 
formulations are presented in Table 1. 
Formulations F1-F4 were modified with either 
CTAB or chitosan in order to confer positive 
charge on the particles. Two of the formulations 
were modified with CTAB pre-dissolved in either 
aqueous phase (F1) or oil phase (F2). Another 
two formulations were modified by either LCS 
(F3) or MCS (F4). The oil phase was mixed with 
the aqueous phase (Table 1) and homogenised 
at about 20,500 rpm for 3 min using IKA® T10 
basic homogeniser (IKA Werke GmbH and Co., 
Germany). The resulting emulsion was added to 
the dispersion medium and stirred for 2 h under 
vacuum. For F5, pDNA was encapsulated within 
the nanoparticles after complexing it with CTAB. 
The pDNA was complexed with CTAB at a 1:1 
molar ratio, and the resultant precipitate was 
collected by centrifugation at 14,000 g for 5 min, 
and rinsed with deionised water. The supernatant 
was discarded and the precipitated complex was 
dried at 50 °C for 15 min. The dried CTAB-pDNA 
complex was dissolved in glacial acetic acid 
(GAA) before being added to the oil phase. Like 
F1 and F2, the oil phase was homogenised with 
the aqueous phase and then added to the 
dispersion medium. The nanoparticles were 
collected by centrifugation, and washed and 
suspended in one millilitre of deionised water. 
Part of each formulation was kept in suspension 
form in ice bath whereas the other part was 
lyophilised. To calculate the concentration of the 
nanoparticle suspensions, aliquots of about 100 
µL of the nanoparticle suspensions were 
centrifuged and the supernatants were 
discarded. This was followed by complete drying 
of the nanoparticles. Nanoparticle suspension 
concentration was calculated by dividing the 
weight of dried nanoparticles by the volume of 




To determine the particle size and zeta potential, 
each nanoparticle suspension was diluted with 
deionised water and analysed by dynamic light 
scattering. For determination of the particle size, 
Malvern Zetasizer Nano Series Nano-S was 
used, while for the determination of zeta 
potential, Nano-Z was utilised (Malvern 
Instruments Ltd, Malvern, Worcestershire, UK). 
The polydispersity index (PdI), which is a 
dimensionless number indicating the width of the 
size distribution (values range between 0 and 1), 
was also obtained from the particle size 
measurement. 
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Table 1: Composition of the nanoparticle formulations 
 
Medium F1 F2 F3 F4 F5 
Oil phase PLGA: 1 % w/v 
DCM:EA (1:5) 
PLGA: 1 % w/v 
CTAB: 1 % w/v 
DCM:EA (1:1) 
PLGA: 1 % w/v 
DCM:EA (1:5) 
PLGA: 1 % w/v 
DCM:EA (1:5) 
PLGA: 1 % w/v 
DCM:EA:GAA (1:4:1) 
pDNAa: 1 % w/v 
Aqueous 
phase 
1 % w/v PVA 
1 % w/v CTAB 
1 % w/v PVA 1 % w/v PVA 
1 % w/v LCS 
1 % w/v PVA 
1 % w/v MCS 




1 % w/v CTAB Deionised 
water  
1 % w/v LCS 1 % w/v MCS Deionised water 
apDNA already complexed with CTAB and dissolved in glacial acetic acid 
 
For scanning electron microscopy (SEM), dried 
nanoparticles were sprinkled onto aluminium 
stubs pre-pasted with carbon adhesive tapes. 
Samples were sputter-coated with gold and 
viewed using Carl Zeiss Evo® 50 Scanning 
Electron Microscope (Oberkochen, Germany). 
 
Preparation and characterisation of nano-
particle-pDNA (NP-pDNA) complexes 
 
Formulations F1-F4 were used to prepare NP-
pDNA complexes by adsorption of pDNA on the 
nanoparticle surface. An amount of 10 µg pDNA 
from 1 % (w/v) solution in Tris-EDTA (TE) buffer 
was mixed with nanoparticle suspensions. The 
total reaction volume was made up to 100 µL 
with deionised water by gentle mixing using up-
and-down pipetting, and the mixture was 
incubated at room temperature for 1 h without 
shaking. The amounts of nanoparticles were 
varied and yielded NP:pDNA weight ratios of 5:1, 
10:1, 20:1 and 50:1. The complex formation was 
verified by gel retardation. The NP-pDNA 
complexes were also subjected to zeta potential 
measurement. 
 
NP-pDNA complexes and pDNA encapsulated 
F5 were examined for their ability to protect 
pDNA from serum by agarose gel 
electrophoresis as described by Agarwal et al [7]. 
Foetal bovine serum (FBS) was added to the NP-
pDNA complexes to a final concentration of 10 % 
FBS and incubated at 37 °C for 1 h or 24 h. 
Immediately following the incubation, 5 µL of 0.5 
M EDTA was added and the samples were 
placed on ice to inhibit DNA nuclease. The 
control was naked pDNA-treated as NP-pDNA 
complexes. The samples and the control were 
loaded on agarose gel and run for 1 h, as 
described earlier [7]. 
 
Release profile study 
 
NP-pDNA complexes at NP/pDNA ratio of 20:1, 
and F5 were subjected to release profile study in 
phosphate buffer (pH 7.2) at 37 °C with shaking 
at 120 rpm to avoid nanoparticle precipitation, 
using a rotary incubator shaker (Innova 4000; 
New Brunswick Scientific Inc., Edison, NJ). The 
nanoparticles were collected by centrifugation at 
seven pre-determined time intervals (3 h, 6 h, 12 
h, 1 day, 3 days, 7 days, and 14 days). Then, the 
supernatant fractions were used to quantify the 
released pDNA by measuring the absorbance at 
260 nm. Thereafter, the nanoparticles were 
re-suspended in equal volume of fresh buffer 
before being withdrawn and returned back to the 
incubator shaker. 
 
Cellular uptake of nanoparticles by murine 
neuroblastoma (N2a) cells  
 
Cellular uptake studies were carried out in 
accordance with the procedures earlier [8]. 
Nanoparticle formulations were prepared with 
inclusion of coumarin-6 as a fluorescent probe. 
Murine neuroblastoma (N2a) cells were seeded 
in a 96-well white flat-bottom microplate at a 
density of 2.5 × 105 cells per well and incubated 
for 48 h at 37 ºC and 5 % CO2. Nanoparticles 
were added to the cells at different 
concentrations: 5 µg, 10 µg and 20 µg per 100 
µL. Following 1 h incubation, the cells were 
washed three times in ice-cold phosphate 
buffered saline (PBS) to remove the non-
internalised nanoparticles. The cells were then 
visualised under an Olympus FSX100 
fluorescence inverted microscope (Olympus, 
Tokyo, Japan).  They were subsequently lysed 
with Promega cell culture lysis buffer (CCLR) 
(Promega; Madison, WI) and then lyophilised. 
This was followed by the solubilisation of 
coumarin-6 with methanol. Finally, the 
fluorescence intensity was measured in a 
fluorescence spectrophotometer (Perkin Elmer 
Corp., Norwalk, CT, USA) at 450 nm excitation 
and 505 nm emission. 
 
Transfection efficiency   
 
Transfection efficiency of pDNA adsorbed on the 
nanoparticles (F1-F4) or encapsulated within the 
particle (F5) was determined by monitoring the 
gene expression of GFP in N2a cells. Cells were 
seeded at a density of 25 × 105 cells per well in a 
24-well flat-bottom microplate and incubated for 
48 h at 37 ºC and 5 % CO2. After that, the media 
were replaced with fresh media containing the 
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nanoparticles and incubated for 48 h. The cells 
were visualised in a Nikon Eclipse Ti 
fluorescence microscope and the captured 
images were analysed with ImageJ (NIH, 
Bethesda, MD, USA) to quantify the green colour 




Comparisons amongst the formulations were 
performed using analysis of variance (ANOVA) 
with Tukey’s post hoc test. Values of p < 0.05 
were considered statistically significant. Minitab 
software version 16 (Minitab, State College, PA) 




Characteristics of nanoparticles 
 
With water as suspending medium, the 
formulation with CTAB-pDNA complex (F5) 
exhibited smaller particle size than the chitosan-
modified nanoparticles (F3 and F4) but was not 
significantly different from the formulation with 
CTAB in oil phase (F2, Figure 1). The 
suspending medium of 10 % FBS strongly 
affected the particle size and the PdI of chitosan-
modified nanoparticles (but not chitosan-free 
nanoparticles, i.e., F1, F2 and F5). The particle 
size of MCS-modified nanoparticles (F4) was 
more affected by serum: it dropped down to 
resemble the non-modified nanoparticles (F5). 
One important feature of all formulations was that 
they did not exhibit any detectable aggregation in 
the presence of serum. This is an essential 
compatibility pre-requisite for in vivo 
administration.  
 
Complexation of nanoparticles with pDNA 
resulted in significant changes in the particle 
sizes of F1, F3 and F4 but not F2. F1 complexed 
with pDNA underwent significant increase in both 
particle size and polydispersity. In contrast, F3 
and F4 had significant reduction in particle size 
when complexed with pDNA. Interestingly, both 
formulations had similar particle size after 
complexation. Furthermore, F1, F3 and F4 
revealed similar particle size when complexed 
with pDNA (p > 0.05). 
 
The two formulations (F1 and F2) which 
contained CTAB as a cationic modifier, did not 
exhibit positive zeta potential (Figure 2). On the 
other hand, chitosan-modified nanoparticles (F3 




Figure 1: Particle size (mean ± standard error) of the nanoparticles suspended in different conditions. Numbers 
over the bars are the PdI ± standard deviation (SD). Significant differences are represented by letters. Groups 
that do not share the same letter are significantly different (p < 0.05) 
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Figure 2: Zeta potential (mean ± standard error) of the nanoparticle formulations after suspending in different 
conditions. Significant differences are represented by letters; groups that do not share a common letter are 
significantly different (p > 0.05) 
 
showed higher zeta potential. F5, in which CTAB 
was already complexed with pDNA, exhibited 
negative zeta potential. When the particles were 
suspended in phosphate buffer, pH 7.2, the zeta 
potential of chitosan-modified nanoparticles (F1 
and F2) was reversed to slightly negative. In the 
presence of 10 % FBS, FBS was shown to 
confer a negative charge to all nanoparticle 
formulations with remarkably lower zeta potential 
in F1 and F2. 
 
The zeta potential values before and after 
lyophilisation were compared. Interestingly, F1 
and F2 manifested zeta potential inversion after 
lyophilisation with no significant difference 
(Figure 2). On the other hand, chitosan-modified 
nanoparticles remained positively charged after 
lyophilisation, but F3 zeta potential decreased 
while that of F4 increased. In contrast to CTAB- 
and chitosan-modified nanoparticles, F5 
remained negatively charged after lyophilisation 
with slight decrease in zeta potential.  
 
Scanning Electron Microscopy (SEM) revealed 
that the formulations had particles with smooth 
surfaces and without visible pores, as shown in 
Figure 3. The particle sizes of F3 and F4 under 
SEM (Figure 3) appeared smaller than the size 




Figure 3: SEM images of nanoparticle formulations 
 
Characteristics of NP-pDNA complex 
 
CTAB- and chitosan-modified nanoparticle 
formulations F1-F4 were used to adsorb pDNA  
Doolaanea et al 




Figure 4: Characterisation of NP-pDNA complexes. (A) Gel retardation assay of the nanoparticles complexed 
with pDNA at different NP:pDNA ratios. Lanes: (1) 1 kb ladder, (2) naked pDNA, (3-6) F1-pDNA complexes at 
ratios 5:1, 10:1, 20:1, 50:1, respectively; (7-10) F2-pDNA complexes at ratios 5:1, 10:1, 20:1, 50:1, respectively; 
(11-14) F3-pDNA complexes at ratios 5:1, 10:1, 20:1, 50:1, respectively; (15-18) F4-pDNA complexes at ratios 
5:1, 10:1, 20:1, 50:1, respectively; (19) F5, (20) CTAB-pDNA complex suspension. (B) Protection of pDNA in NP-
pDNA complexes at ratio 20:1 from degradation in 10 % FBS. Lanes: (1) 1 kb ladder, (2) naked pDNA, (3) naked 
pDNA incubated in 10 % FBS for 1 h, (4-7) NP-pDNA ratio 20:1 complexes incubated in 10 % FBS for 1 h, (8) F5 
incubated in 10 % FBS for 1 h, (9-12) NP-pDNA ratio 20:1 complexes incubated in 10 % FBS for 24 h, (13) F5 




Figure 5: Zeta potential of the NP-pDNA complexes at different NP/pDNA ratios: F1 (●); F2 (■); F3 (▲); F4 (▼) 
 
on the particle surface. The adsorption was 
evaluated by gel retardation (Figure 4) and zeta 
potential measurement (Figure 5) at different 
NP:pDNA ratios. Although F1 revealed negative 
zeta potential, it could complex with pDNA but 
not completely, even at high NP:pDNA ratio. In 
addition, the pattern of pDNA migration on the 
gel at ratios 20:1 and 50:1 appeared similar to 
that when CTAB-pDNA complex was subjected 
to gel electrophoresis (lane 20 in Figure 4A). 
Zeta potential measurement revealed that F1-
pDNA complexes at different ratios were 
negatively charged. F2, on the other hand, could 
not adsorb pDNA efficiently because free pDNA 
was detected in all ratios. Moreover, zeta 
potential showed negative charge that was 
similar in all ratios. In contrast, chitosan-modified 
nanoparticles (F3 and F4) adsorbed pDNA even 
at the lowest NP:pDNA ratio. In addition, zeta 
potential of the NP-pDNA complexes for F3 and 
F4 increased gradually with increase in 
NP:pDNA ratio. 
 
The stabilities of the pDNA complexes were 
evaluated using agarose gel electrophoresis after 
incubating NP-pDNA complexes (ratio 20:1) in 
Doolaanea et al 
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the presence of serum (10 % FBS) for 1 h and 
for 24 h (Figure 4B). The naked pDNA was 
completely degraded during the first hour of 
incubation. In contrast, F1-4 (lanes 4-7, Figure 
4B) exhibited partial pDNA protection during 1 h 
incubation. F1 and F2 (lanes 4-5, Figure 4B) 
showed the least protection while F4 (lane 8, 
Figure 4B) showed the highest protection. On the 
other hand, F5 did not show any sign of 
smearing but only intense spot in the well. 
Overall, following 24 h incubation, only F4 and 
F5 conferred considerable stability on the pDNA. 
 
 
Figure 6: Release profile of F5 and NP-pDNA 
complexes at ratio 20:1 (nanoparticles: pDNA) over 2 
weeks: F1 (♦); F2 (■); F3 (∆); F4 (▲); F5 (□) 
 
Results from in vitro release study 
 
F5 and NP-pDNA complexes (ratio 20:1) were 
subjected to release profile study over 2 weeks 
(Figure 6). Plasmid DNA adsorbed on the particle 
surface (F1-F4) exhibited high burst release (~50 
- 80 % within 24 h). F2, which poorly adsorbed 
and protected the pDNA, revealed the highest 
burst release (79.4 % within 24 h) followed by 
slow release of the remaining pDNA. 
Interestingly, F2, F3 and F4 displayed almost 
similar burst release within 24 h (60.6, 62.3 and 
58.1 %, respectively). On the other hand, F5 
showed low burst release (only 12.9 % within 24 
h) followed by sustained release, with a total of 
38.9 % released over the 2 weeks. 
 
 
Cellular uptake of nanoparticles by N2a cells 
 
The results revealed that within each chitosan- 
free nanoparticle formulation (F1, F2 and F5), 
there was no significant difference in cellular 
uptake at all the tested concentrations (Figure 7 
and Figure 8). In contrast, chitosan-modified 
nanoparticles (F3 and F4) showed increases in 
cellular uptake with increases in nanoparticle 
concentration. 
 
Degree of transfection of N2a cells 
 
Nanoparticles loaded with pDNA (encoding 
GFP), either by encapsulation (F5) or by 
adsorption (F1-F4), were used to transfect N2a 
cells. F2 exhibited higher transfection than F1 
(Table 2); the latter almost did not show any 
gene expression. Chitosan-modified  
 
 
Figure 7: Quantitation of the cellular uptake of coumarin-6 loaded nanoparticles by N2a cells. Significance 
differences are represented by letters. Groups that do not share a common letter are significantly different 
(p < 0.05)
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nanoparticles exhibited different transfection 
efficiencies at different ratios; F3 and F4 showed 
the highest transfection at ratios 20:1 and 50:1, 
respectively. Amongst all formulations, F5 
revealed the highest transfection. At the low NP-
pDNA ratio of 5:1, F2 exhibited the highest 
transfection but at the high ratio of 50:1, F3 




Figure 8: Cellular uptake of coumarin 6-loaded 
nanoparticles by N2a as viewed by fluorescence 
microscopy. Arrows denote free particles present in 




Chitosan adsorption and the high viscosity of the 
aqueous phase were responsible for the 
increased particle size of chitosan-modified 
nanoparticle [9]. Serum contents could adsorb on 
the particle surface and may influence the 
particle size, polydispersity and zeta potential 
[11]. Schulze  et  al [12] reported de-
agglomeration while Nafee et al [13] reported 
agglomeration and increased particle size in the 
presence of serum. In contrast to the report of 
Nafee et al [13], it was found in this study that F3 
and F4 exhibited decreased particle size in 10 % 
FBS. 
 
It has been suggested that chitosan adsorption 
on PLGA particles followed the multi-layer 
pattern with different conformations [9]. Serum 
components (zeta potential = -16.7 ± 0.7 mV) 
could adsorb on the nanoparticle surface causing 
chitosan to desorb, and its conformation could 
also become more compacted. Like the effect of 
serum, compaction of chitosan layers due to the 
adsorption of pDNA was responsible for the 
particle size decrease of chitosan-modified 
nanoparticles.  
 
Table 2: Quantitation of transfection of N2a with pDNA 
(encoding GFP)-loaded nanoparticles 
  




F1 5:1 0 ± 0 (c) 
 10:1 0.541 ± 0.103 (e) 
 20:1 0.19  ± 0.06 (h) 
 50:1 0 ± 0 (j) 
F2 5:1 10.333  ± 1.155 (a) 
 10:1 4.667  ± 0.577 (e) 
 20:1 100.33  ± 30.66 (f) 
 50:1 52.67  ± 7.09 (j) 
F3 5:1 0.593  ± 0.090 (c) 
 10:1 28.0  ± 4.359 (d) 
 20:1 50.0  ± 13.23 (g) 
 50:1 142.33  ± 46.32 (i) 
F4 5:1 7.333 ± 1.155 (b) 
 10:1 25.667  ± 4.041 (d) 
 20:1 139.67  ± 18.01 (f) 
 50:1 62.67  ± 11.02 (j) 
F5 - 227.33  ± 12.50 
Untreated cells - 0.23  ± 0.2 
Negative 
control 
- 0 ± 0 
Positive 
control 
- 0.86  ± 0.14 
Significant differences amongst different formulations 
of each of the NP:pDNA ratio were denoted by letters. 
Groups that do not share a letter differ significantly (p 
< 0.05). F5 was significantly different from all other 
formulations with different ratios and also significantly 
different from positive and negative controls. 
(aTransfection efficiency was calculated as relative 
area of the green color in the captured images and 
reported as relative area × 1000) 
 
Electrolytes cause compression of the double 
layers around the particles, leading to decrease 
in the absolute value of zeta potential [9]. This 
effect was clearly observed where all 
formulations had slightly negative zeta potential 
in phosphate buffer. In addition, the non-specific 
adsorption of serum components [12,13] was 
responsible for the negative zeta potential of all 
formulations in 10 % FBS. The inversion of zeta 
potential values of F1 and F2 could be explained 
by the re-localisation and re-orientation of CTAB. 
During the lyophilisation, CTAB molecules may 
migrate to the surface of the particles orienting 
their polar head to the surface in a manner 
similar to that of micelle conformation. The 
change of zeta potential of chitosan-modified 
nanoparticles after lyophilisation may be 
attributed to the change in chitosan 
conformation. In contrast, F5 exhibited the best 
stability of zeta potential before and after 
lyophilisation. 
 
Doolaanea et al 
Trop J Pharm Res, January 2018; 17(1): 9 
 
A gene delivery vehicle should be able to protect 
pDNA under physiological conditions so that it 
can reach the target cell. The results of this study 
are in line with the general observation that high 
molecular weight chitosan produced more stable 
complexes with pDNA [14]. F5 offered the best 
protection to pDNA in the presence of serum due 
to encapsulation of the pDNA inside the particles. 
Furthermore, pre-complexation of pDNA with 
CTAB, followed by encapsulation within PLGA 
dramatically reduced the burst release of F5. 
This is of advantage because it would help to 
avoid the loss of pDNA before it reaches the 
target cell. 
 
Particle  surface plays important role in cellular 
uptake [8]. Chitosan-modified nanoparticles 
exhibited higher cell uptake despite the negative 
zeta potential in the presence of 10 % FBS. 
Thus, there could be other factors involved in the 
enhancement effect of chitosan on cell uptake. 
Since nanoparticle uptake is the balance 
between endocytosis and exocytosis, chitosan 
may reduce the exocytosis aspect. The 
observation of free nanoparticles in the medium 
with F2 and F5 may be attributed to exocytosis 
since both formulations were chitosan-free.  
 
The unexpected high transfection observed in F2 
may be attributed to the weak interaction with 
pDNA. Similar results had been obtained by 
Köping-Höggård et al [15] who reported that 
polyplexes with easier dissociations yielded 
higher gene expression. The transfection 
efficiency of chitosan-modified nanoparticles is in 
line with the zeta potential measurements of the 
NP-pDNA complexes. The high stability of pDNA 
in F5 might be responsible for its high 
transfection efficiency. Thus, the transfection 
efficiency was a consequence of synergistic 
effects of different factors such as the strength of 
interaction between pDNA and nanoparticles, 
pDNA stability, zeta potential, cellular uptake and 




It is evident from the results obtained in the 
present study that the method of loading pDNA 
within PLGA nanoparticles influences the 
characteristics of the nanoparticles. This 
encapsulation loading method produces better 
results than the adsorption method. 
Encapsulation of pDNA as CTAB-pDNA complex 
in PLGA nanoparticles is a more effective 
technique for delivering pDNA for gene therapy 
than adsorption of pDNA on the particle surface. 
This encapsulation method also leaves the 
particle surface free for further modification that 
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